Clinical trial
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
NCT06685068 is registered in ClinicalTrials.gov with Genmab as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
- Lead sponsor
- Genmab
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- November 13, 2024
- Completion date
- March 30, 2026
- Enrollment
- 23 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
advanced solid tumor